the current landscape of biosimilars in ibd
Published 4 years ago • 976 plays • Length 16:44Download video MP4
Download video MP3
Similar videos
-
16:48
biosimilars in ibd: where do we stand today?
-
18:23
biosimilars for ibd: to start, switch, or stay away?
-
23:20
biosimilars for ibd: when to start, switch, or stay away?
-
16:22
incorporating ibd biosimilars into practice: patient care and education
-
20:47
biosimilars for ibd: start, switch, or stay away?
-
15:27
status of biosimilars in us & experience from asia & europe
-
14:19
regulatory pathway for biosimilars
-
21:21
beyond reference biologics: biosimilars on the horizon
-
9:02
debate: biosimilar therapies - use as indicated, in place of our current biologics
-
1:40
navigating the ibd landscape: the impact of biosimilars on cost, care, and the future of healthcare
-
11:03
biosimilars in the us and beyond
-
41:15
targeting ibd: hitting the mark in today’s treatment landscape
-
23:44
mechanisms of disease: biologic pipeline for ibd
-
39:48
optimizing biosimilars for safe and effective management of imids
-
13:19
what are biosimilar therapies and why should we care?
-
1:47
understanding biosimilars - for ibd patients
-
11:40
debate: biosimilar therapies - caution, more studies are needed
-
22:41
the evolving clinical landscape for ulcerative colitis
-
4:04
biosimilars and inflammatory bowel disease